The Effect of a Combination of Orange- and Pomegranate Actives on Physical Fitness in Elderly People

Sponsor
BioActor (Industry)
Overall Status
Completed
CT.gov ID
NCT03781999
Collaborator
(none)
37
1
2
6.8
5.5

Study Details

Study Description

Brief Summary

The primary objective of this study is to determine the effect of daily supplementation of a combined orange- and pomegranate extract for a period of 4 weeks on physical fitness compared to placebo.

In this crossover study, participants will daily receive either a placebo or Actiful®, a supplement containing 500 mg orange extract and 200 mg pomegranate actives, for 4 weeks followed by a wash-out period of 4 to 8 weeks. Subsequently, the second intervention period of 4 weeks (active product or placebo) will take place. The product and placebo will be supplied in capsules that participants can ingest with a glas of water (daily, prior to breakfast).

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Actiful
  • Other: Placebo
N/A

Detailed Description

Dietary habits and physical activity are two important components of a healthy lifestyle. Targeted nutritional interventions may improve health and stimulate physical activity. Both orange extracts and pomegranate concentrate have been shown to exert beneficial effects on health and exercise performance. However, the effects of a combination of the two extracts on exercise and physical activity have not been investigated yet. It is expected that this combination may be an effective dietary way to improve exercise performance, physical activity in the free-living state, and quality of life in a middle aged population.

Study Design

Study Type:
Interventional
Actual Enrollment :
37 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Double (Participant, Investigator)
Primary Purpose:
Supportive Care
Official Title:
The Effect of a Combination of Orange- and Pomegranate Actives on Physical Fitness in Elderly People
Actual Study Start Date :
Jun 25, 2018
Actual Primary Completion Date :
Jan 17, 2019
Actual Study Completion Date :
Jan 17, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Actiful

a supplement containing 500 mg orange extract and 200 mg pomegranate actives

Dietary Supplement: Actiful
supplement containing 500 mg orange extract and 200 mg pomegranate actives

Placebo Comparator: Placebo

Maltodextrin

Other: Placebo
Maltodextrin

Outcome Measures

Primary Outcome Measures

  1. 6 Minute Walking Test [0-4-8-12 weeks]

    Participants have to walk for 6 minutes, as fast as possible. Total distance will be measured.

Secondary Outcome Measures

  1. Senior Fitness test [0-4-8-12 weeks]

    Fitness tests to see if Actiful improves physical activity level

  2. Daily physical activity measured by accelerometers [0-4-8-12 weeks]

    Accelerometer is worn for 7 days prior to each testing day

  3. Quality of life questionnaire - WHOQOL-100 [0-4-8-12 weeks]

    Participants will be asked to fill out the WHOQOL-100 questionnaire to determine quality of life. Scale from 1-5 (disagree-agree)

  4. Concentration of blood marker TAC [0-4-8-12 weeks]

    Total antioxidant capacity measurement in plasma

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 60 - 75 years old

  • non smoking

  • BMI 18 -28 kg/m²

Exclusion Criteria:
  • Allergy to test product/placebo or citrus fruits

  • BMI lower than 18 or higher than 28

  • Recent muscle injury in less than one month before the start of the study

  • Inability to perform the fitness tests

  • Medical conditions that might influence outcome measure or participant safety during testing, including but not limited to: severe cardiovascular disease, cancer, Parkinson's disease. To be decided by PI.

  • High blood pressure (systolic ≥ 140 mmHg, diastolic ≥ 90 mmHg)

  • Use of medication that may interfere with the study results, use of beta-blockers

  • Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 180 days prior to the study

  • Abuse of products; alcohol (> 20 alcoholic units per week) and drugs

Contacts and Locations

Locations

Site City State Country Postal Code
1 BioActor Maastricht Netherlands 6229GS

Sponsors and Collaborators

  • BioActor

Investigators

  • Principal Investigator: Freddy Troost, Dr, Maastricht University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BioActor
ClinicalTrials.gov Identifier:
NCT03781999
Other Study ID Numbers:
  • Actiful_001
First Posted:
Dec 20, 2018
Last Update Posted:
Jun 24, 2019
Last Verified:
Jun 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by BioActor

Study Results

No Results Posted as of Jun 24, 2019